UTICA, N.Y. — ConMed Corporation (NASDAQ: CNMD) on Wednesday announced that it is transferring the listing of its common stock to the New York Stock Exchange (NYSE) from the NASDAQ Global Market.
The Utica–based surgical-device manufacturer expects to begin trading on the NYSE effective at the open of markets on Feb. 10, the firm announced.
“We are excited to be joining the NYSE on the actual day of ConMed’s 50th anniversary. With this move, we join the group of high-performing medical-device companies traded on the NYSE. We are grateful for the long and valued partnership with NASDAQ and look forward to a productive relationship with the NYSE,” Curt Hartman, CEO of ConMed, said in a statement.
(Sponsored)
The Pay Transparency Laws Become Effective On September 17th. Are You Ready?
Later this month New York will join a handful of States in the US which require greater transparency in wages. In December 2022, the Governor signed into law new wage
The Importance of Relationship Banking for Small Business Success
Small business owners wear many hats. Each day can bring on new challenges requiring valuable time and focus – especially in the competitive economic environment we live in today. The
The company’s shares will continue to trade on the NASDAQ until the transfer is completed and will continue to trade under the ticker “CNMD” after the move to the NYSE.
“We are delighted to welcome ConMed, an innovator in the medical device industry, as it transfers its listing to the NYSE,” John Tuttle, vice chairman and chief commercial officer of NYSE Group. “We look forward to collaborating with the company and continuously delivering the benefits of our unique market model and world-class services.”
ConMed is a medical technology company that produces surgical devices and equipment for minimally invasive procedures. The firm’s products are used by surgeons and physicians in specialties that include orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology.
For the full year of 2019, ConMed posted net income of $28.6 million, or 97 cents a share, down 31 percent from $40.8 million, or $1.41 a share, during 2018.
Contact Reinhardt at ereinhardt@cnybj.com
